健康元(600380.SH)：針對COPD的TSLP單抗正在推進二期臨牀，目前進度居國內前列
格隆匯7月29日丨健康元(600380.SH)在互動平臺表示，公司近年來持續加大在創新藥領域的研發投入，當前已有多個1類創新藥和具有全球差異化競爭力的創新藥項目進入臨牀關鍵階段截止現在已佈局二十餘款 1 類創新藥，其中超過 10 款已進入二期臨牀及以後階段，各項目均按計劃有序推進。近期公司創新藥的研發新進展主要包括： 1）流感治療領域，針對 12 歲至成人患者的瑪帕西沙韋膠囊正處於報產階段，目前進展順利；同時，專注兒童流感的瑪帕西沙韋幹混懸劑已取得 IND 批準，正在推進一期臨牀。兩款藥物分別針對不同年齡段患者設計，有望爲全人羣流感治療提供更適配的選擇。 2）在呼吸慢病領域，針對 COPD 的TSLP單抗正在推進二期臨牀，目前進度居國內前列；全球 FIC 靶點 PREP 抑制劑已完成一期臨牀，正在推進二期臨牀；該佈局延續了公司在 COPD 賽道的深耕 。COPD 作爲高發慢性呼吸疾病，患者數量龐大且持續增長，現有治療中難以有效控制炎症，導致症狀持續加重，反覆急性發作等問題尚未解決，這些藥物有望爲這一領域帶來新的治療方案。 3）鎮痛領域的非阿片類鎮痛創新藥鈉離子 1.8 抑制劑已完成一期臨牀，正在推進二期臨牀，旨在規避傳統阿片類藥物的成癮性等風險，助力減少阿片類藥物使用，爲鎮痛治療提供更安全的選擇。 4）自免領域的 IL-17A/F 單抗三期臨牀已達到主要終點，該藥物優勢顯著。在與全球 IL-17A 靶點標杆藥物司庫奇尤單抗（可善挺 ®）的頭對頭研究中，展現出起效更快、短期療效更優、長期療效強效持久的特點，且給藥間隔可延長，同時安全性良好。 未來，公司將持續聚焦呼吸、鎮痛、自免等重點治療領域中尚未被滿足的臨牀需求，以差異化管線佈局爲核心強化競爭力。我們將加快推進各階段在研項目的臨牀開發進程，持續推動產品從臨牀價值向市場轉化的落地進程，爲患者提供更安全、更有效的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
